相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy
Giselle M. Boukhaled et al.
NATURE IMMUNOLOGY (2022)
COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets
Toni M. Delorey et al.
NATURE (2021)
Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling
Michael C. Brown et al.
NATURE COMMUNICATIONS (2021)
Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma
Georgia M. Beasley et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB-IVM1c melanoma (MEL)
A. Ribas et al.
ANNALS OF ONCOLOGY (2021)
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer
Paula Voabil et al.
NATURE MEDICINE (2021)
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
Harriet M. Kluger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
Caroline Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
Alexander C. Huang et al.
NATURE MEDICINE (2019)
Determining cell type abundance and expression from bulk tissues with digital cytometry
Aaron M. Newman et al.
NATURE BIOTECHNOLOGY (2019)
Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis
Qiaofen Fu et al.
ONCOIMMUNOLOGY (2019)
High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling
Maria I. Toki et al.
CLINICAL CANCER RESEARCH (2019)
Clonal replacement of tumor-specific T cells following PD-1 blockade
Kathryn E. Yost et al.
NATURE MEDICINE (2019)
The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors
Kyung Hwan Kim et al.
CLINICAL CANCER RESEARCH (2019)
Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy
Imran Siddiqui et al.
IMMUNITY (2019)
The Immune System Computes the State of the Body: Crowd Wisdom, Machine Learning, and Immune Cell Reference Repertoires Help Manage Inflammation
Irun R. Cohen et al.
FRONTIERS IN IMMUNOLOGY (2019)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity
Brendan L. Horton et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs
Michael C. Brown et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma
Nicolas Jacquelot et al.
ONCOIMMUNOLOGY (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
Priti S. Hegde et al.
CLINICAL CANCER RESEARCH (2016)
Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models
Eda K. Holl et al.
ONCOTARGET (2016)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Induction of Viral, 7-Methyl-Guanosine Cap-Independent Translation and Oncolysis by Mitogen-Activated Protein Kinase-Interacting Kinase-Mediated Effects on the Serine/Arginine-Rich Protein Kinase
Michael C. Brown et al.
JOURNAL OF VIROLOGY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma
Gulsun Erdag et al.
CANCER RESEARCH (2012)
An Oncolytic Adenovirus Enhanced for Toll-like Receptor 9 Stimulation Increases Antitumor Immune Responses and Tumor Clearance
Vincenzo Cerullo et al.
MOLECULAR THERAPY (2012)
Function and regulation of MHC class II molecules in T-lymphocytes: Of mice and men
TM Holling et al.
HUMAN IMMUNOLOGY (2004)
Serine protease inhibitor 2A is a protective factor for memory T cell development
N Liu et al.
NATURE IMMUNOLOGY (2004)
Intergeneric poliovirus recombinants for the treatment of malignant glioma
M Gromeier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
